| Company Name: |
3B Pharmachem (Wuhan) International Co.,Ltd.
|
| Tel: |
821-50328103-801 18930552037 |
| Email: |
3bsc@sina.com |
| Products Intro: |
Product Name:O-1602;5-Methyl-4-[(1R,6R)-3-Methyl-6-(1-cyclohexen-1-yl]-1,3-benzenediol
CAS:317321-41-8
Purity:99% HPLC Package:1Mg ; 5Mg;10Mg ;100Mg;250Mg ;500Mg ;1g;2.5g ;5g ;10g
|
| Company Name: |
Beijing Yisiyan Technology Research Center
|
| Tel: |
010-56645598 13366904824 |
| Email: |
bjkaida@163.com |
| Products Intro: |
Product Name:5-METHYL-4-[(1R,6R)-3-METHYL-6-(1-METHYLETHENYL)-2-CYCLOHEXEN-1-YL]-1,3-BENZENEDIOL
CAS:317321-41-8
Package:100mg;500mg;1000mg
|
| Company Name: |
EMMX Biotechnology LLC
|
| Tel: |
888-539-0666 |
| Email: |
info@emmx.com |
| Products Intro: |
Product Name:O-1602
CAS:317321-41-8
Purity:98% HPLC Package:5mg;10mg;25mg;50mg;100mg;250mg;500mg;1g
|
|
| | 5-METHYL-4-[(1R,6R)-3-METHYL-6-(1-METHYLETHENYL)-2-CYCLOHEXEN-1-YL]-1,3-BENZENEDIOL Basic information |
| Product Name: | 5-METHYL-4-[(1R,6R)-3-METHYL-6-(1-METHYLETHENYL)-2-CYCLOHEXEN-1-YL]-1,3-BENZENEDIOL | | Synonyms: | 5-METHYL-4-[(1R,6R)-3-METHYL-6-(1-METHYLETHENYL)-2-CYCLOHEXEN-1-YL]-1,3-BENZENEDIOL;O-1602;5-Methyl-4-[(1R,6R)-3-methyl-6-(1-cyclohexen-1-yl]-1,3-benzenediol;1,3-Benzenediol, 5-methyl-4-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-;O 1602,O1602 | | CAS: | 317321-41-8 | | MF: | C17H22O2 | | MW: | 258.36 | | EINECS: | | | Product Categories: | Cannabinoid receptor | | Mol File: | 317321-41-8.mol | ![5-METHYL-4-[(1R,6R)-3-METHYL-6-(1-METHYLETHENYL)-2-CYCLOHEXEN-1-YL]-1,3-BENZENEDIOL Structure](CAS/GIF/317321-41-8.gif) |
| | 5-METHYL-4-[(1R,6R)-3-METHYL-6-(1-METHYLETHENYL)-2-CYCLOHEXEN-1-YL]-1,3-BENZENEDIOL Chemical Properties |
| Boiling point | 401.6±45.0 °C(Predicted) | | density | 1.073±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in methyl acetate (supplied pre-dissolved -10mg/ml) | | form | Powder | | pka | 9.92±0.45(Predicted) |
| | 5-METHYL-4-[(1R,6R)-3-METHYL-6-(1-METHYLETHENYL)-2-CYCLOHEXEN-1-YL]-1,3-BENZENEDIOL Usage And Synthesis |
| Description | O-1602 is an agonist of GPR55 (EC50 = 13 nM in a GTPγS binding assay) and a derivative of the GPR55 agonist abnormal cannabidiol . It is selective for GPR55 over cannabinoid (CB) receptor 1 (CB1) and CB2 (EC50s = >30 μM for both in GTPγS binding assays). O-1602 (50 μM) reduces growth of Mz-ChA-1, HuCCT-1, CC-LP-1, and SG231 cholangiocarcinoma cells and reduces tumor growth in a Mz-ChA-1 mouse xenograft model when administered at a dose of 10 mg/kg per day. O-1602 increases calcium mobilization and lipogenesis in 3T3-L1 adipocytes in a concentration-dependent manner and increases food intake and fat mass in rats; however, this effect was also observed in mice lacking GPR55. O-1602 reduces movement-induced firing of nociceptive C fibers in a rat model of inflammatory joint pain. It also decreases IL-6 and TNF-α levels and myeloperoxidase activities in the plasma, lungs, and pancreas in a mouse model of acute pancreatitis. | | Uses | O-1602 is an analog of cannabidiol that is a potent agonist at the GPR55 cannabinoid receptor. | | Biological Activity | Analog of cannabidiol that is a potent agonist at the GPR55 cannabinoid receptor (EC 50 values are 13, > 30000 and > 30000 nM for GPR55, CB 1 and CB 2 receptors respectively). Induces activation of RhoA, cdc42 and rac1. | | storage | Store at -20°C |
| | 5-METHYL-4-[(1R,6R)-3-METHYL-6-(1-METHYLETHENYL)-2-CYCLOHEXEN-1-YL]-1,3-BENZENEDIOL Preparation Products And Raw materials |
|